- Home
- BYSI vs CSBR Comparison
BYSI vs CSBR Comparison
Compare BYSI & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BYSI
- CSBR
- Stock Information
- Founded
- BYSI 2010
- CSBR 1985
- Country
- BYSI United States
- CSBR United States
- Employees
- BYSI N/A
- CSBR N/A
- Industry
- BYSI Biotechnology: Pharmaceutical Preparations
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BYSI Health Care
- CSBR Health Care
- Exchange
- BYSI Nasdaq
- CSBR Nasdaq
- Market Cap
- BYSI 79.0M
- CSBR 90.0M
- IPO Year
- BYSI 2017
- CSBR 1986
- Fundamental
- Price
- BYSI $2.18
- CSBR $7.01
- Analyst Decision
- BYSI
- CSBR Strong Buy
- Analyst Count
- BYSI 0
- CSBR 1
- Target Price
- BYSI N/A
- CSBR $12.00
- AVG Volume (30 Days)
- BYSI 47.9K
- CSBR 12.0K
- Earning Date
- BYSI 11-13-2025
- CSBR 12-10-2025
- Dividend Yield
- BYSI N/A
- CSBR N/A
- EPS Growth
- BYSI N/A
- CSBR N/A
- EPS
- BYSI N/A
- CSBR 0.21
- Revenue
- BYSI N/A
- CSBR $56,878,000.00
- Revenue This Year
- BYSI N/A
- CSBR $7.31
- Revenue Next Year
- BYSI N/A
- CSBR $12.01
- P/E Ratio
- BYSI N/A
- CSBR $32.76
- Revenue Growth
- BYSI N/A
- CSBR 10.11
- 52 Week Low
- BYSI $0.98
- CSBR $4.07
- 52 Week High
- BYSI $3.44
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- BYSI 60.33
- CSBR 54.41
- Support Level
- BYSI $1.86
- CSBR $6.67
- Resistance Level
- BYSI $2.21
- CSBR $6.87
- Average True Range (ATR)
- BYSI 0.15
- CSBR 0.16
- MACD
- BYSI 0.02
- CSBR 0.01
- Stochastic Oscillator
- BYSI 77.68
- CSBR 55.29
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.